1801.HK Innovent Biologics, Inc. Loading...

Loading chart...
Top Calls
Feed
Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
06:40
Apr 27
Rebecca Liang Reporter, The Block Bloomberg Markets
Long Innovent Biologics and Hengrui Medicine.
She recommends Innovent Biologics and Hengrui Medicine as top picks in the Chinese pharmaceutical sector. Innovent is a maturing biopharma transitioning to global level with a strong pipeline and deal-making capability. Hengrui is a traditional company successfully phasing out legacy products and replenishing with innovative drugs. Both have clinical catalysts and are positioned to benefit from China's growing dominance in global drug R&D.
1801.HK 1ST
HIGH

About 1801.HK Analyst Coverage

Buzzberg tracks 1801.HK (Innovent Biologics, Inc.) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade ideas tracked.